Perceptive Advisors LLC lifted its position in Quotient Ltd (NASDAQ:QTNT) by 23.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,289,054 shares of the company’s stock after acquiring an additional 2,500,000 shares during the period. Quotient accounts for approximately 2.5% of Perceptive Advisors LLC’s investment portfolio, making the stock its 13th biggest holding. Perceptive Advisors LLC owned about 0.17% of Quotient worth $126,378,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Broadfin Capital LLC raised its holdings in shares of Quotient by 225.1% during the fourth quarter. Broadfin Capital LLC now owns 1,994,183 shares of the company’s stock worth $18,965,000 after purchasing an additional 1,380,754 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Quotient by 47.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,500,000 shares of the company’s stock valued at $23,775,000 after acquiring an additional 800,000 shares during the period. Credit Suisse AG lifted its holdings in Quotient by 46.4% in the fourth quarter. Credit Suisse AG now owns 2,443,068 shares of the company’s stock valued at $23,234,000 after acquiring an additional 774,814 shares during the period. Artisan Partners Limited Partnership boosted its position in Quotient by 51.5% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,264,606 shares of the company’s stock worth $12,026,000 after purchasing an additional 429,705 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Quotient by 74.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 411,800 shares of the company’s stock worth $3,200,000 after purchasing an additional 175,287 shares in the last quarter. Institutional investors own 74.33% of the company’s stock.
In related news, CFO Peter Buhler purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $4.04 per share, with a total value of $40,400.00. Following the purchase, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $40,400. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Prondzynski Heino Von acquired 30,000 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $120,000.00. Following the completion of the acquisition, the director now owns 239,922 shares in the company, valued at approximately $959,688. The disclosure for this purchase can be found here. 14.20% of the stock is owned by insiders.
QTNT has been the subject of several recent research reports. Zacks Investment Research raised shares of Quotient from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a report on Wednesday, January 8th. ValuEngine upgraded shares of Quotient from a “hold” rating to a “buy” rating in a research report on Saturday, February 1st. Finally, BidaskClub cut shares of Quotient from a “sell” rating to a “strong sell” rating in a report on Friday, January 31st.
Shares of NASDAQ:QTNT traded up $0.37 during trading on Thursday, reaching $3.75. 691,161 shares of the company’s stock traded hands, compared to its average volume of 564,171. The company has a quick ratio of 5.67, a current ratio of 6.43 and a debt-to-equity ratio of 9.74. Quotient Ltd has a fifty-two week low of $2.39 and a fifty-two week high of $11.30. The company has a 50-day simple moving average of $5.68 and a 200-day simple moving average of $7.69. The firm has a market cap of $285.50 million, a PE ratio of -2.42 and a beta of 1.15.
Quotient (NASDAQ:QTNT) last released its quarterly earnings results on Thursday, January 30th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. The business had revenue of $7.94 million during the quarter, compared to analyst estimates of $7.10 million. On average, equities research analysts forecast that Quotient Ltd will post -1.48 EPS for the current year.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Article: What is the S&P 500 Index?
Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Ltd (NASDAQ:QTNT).
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.